Jubrele

Desogestrel, the active ingredient in Jubrele, is a progestogen presented as an oral tablet for oral use. It is employed as a hormonal contraceptive to prevent pregnancy in women of reproductive age by suppressing ovulation and altering cervical mucus, providing reliable birth control.

GNH USA supplies Jubrele as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desogestrel is indicated for hormonal contraception, acting within the reproductive hormone pathway to prevent pregnancy.

Contraception (prevention of pregnancy): provides reliable oral hormonal birth control for women of reproductive age.

Desogestrel may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild stomach upset that often resolves with continued use. - Headache: occasional tension‑type headaches. - Breast tenderness: temporary discomfort or swelling. - Irregular bleeding: spotting or changes in menstrual pattern. - Weight gain: slight increase in body weight. - Mood changes: mild emotional fluctuations.

Serious or Rare Side Effects: - Deep vein thrombosis: blood clot formation in the legs. - Pulmonary embolism: clot that travels to the lungs. - Stroke: rare cerebrovascular event. - Severe allergic reaction: rash, swelling, or difficulty breathing. - Liver dysfunction: abnormal liver enzyme levels. - Visual disturbances: sudden changes in vision.

Before prescribing Jubrele, clinicians should evaluate patient history and risk factors. - Smoking status: avoid use in women over 35 who smoke due to increased thrombotic risk. - Cardiovascular disease: contraindicated in patients with history of myocardial infarction or stroke. - Liver disease: use with caution in severe hepatic impairment. - Migraine with aura: avoid because of elevated stroke risk. - Breast cancer: contraindicated in active or past hormone‑sensitive breast cancer. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and direct sunlight.

Desogestrel may interact with several medications that affect its metabolism or increase thrombotic risk.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce contraceptive efficacy. - Anticoagulants (e.g., warfarin): increased risk of clotting disorders. - Hormonal therapies containing estrogen: additive risk of venous thromboembolism.

Moderate Interactions (Monitor Closely): - Antiepileptic drugs (e.g., phenytoin): may modestly lower plasma levels. - Antifungal agents (e.g., ketoconazole): may increase desogestrel exposure. - St. John’s Wort: may decrease effectiveness. - Certain antibiotics (e.g., clarithromycin): potential modest interaction.